ClinicalTrials.Veeva

Menu
S

Southern California Research Center | Coronado, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

EDP-305
Ribavirin
MK-7240
Golimumab
Semaglutide
BMS-650032
Daclatasvir
Faldaprevir
Volixibat
Elafibranor

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 68 total trials

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver).PBC is a slowly progressiv...

Enrolling
Primary Biliary Cholangitis (PBC)
Drug: Elafibranor
Other: Matched 80 mg placebo

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have n...

Enrolling
Non-alcoholic Steatohepatitis (NASH)
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Drug: Placebo
Drug: ALN-HSD

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting
Colitis, Ulcerative
Biological: JNJ-78934804
Drug: Placebo

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severe...

Enrolling
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Placebo
Drug: Eltrekibart

This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with...

Active, not recruiting
Hepatocellular Carcinoma
Drug: Nofazinlimab (CS1003)+Lenvatinib
Drug: Nofazinlimab (CS1003) Placebo+Lenvatinib

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
PBC
Primary Biliary Cholangitis
Drug: Volixibat
Drug: Placebo

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
Primary Sclerosing Cholangitis
Drug: Placebo
Drug: Volixibat

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative col...

Enrolling
Ulcerative Colitis
Drug: IV Placebo
Drug: SC Placebo
Locations recently updated

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's diseas...

Enrolling
Crohn's Disease
Other: SC Placebo
Drug: IV Tulisokibart

A Trial to Investigate the Pharmacokinetics (PK) Effects and Safety Profile of K-808 (Pemafibrate) in Primary Biliary Cholangitis (PBC) Subjects with...

Enrolling
Compensated Cirrhosis
Primary Biliary Cholangitis
Drug: K-808
Locations recently updated

This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of...

Not yet enrolling
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Compensated Liver Cirrhosis
Drug: BI 770371
Drug: Placebo for BI 770371

VAY736 dose testing; VAY736 efficacy and safety testing.

Active, not recruiting
Autoimmune Hepatitis
Other: Placebo
Biological: VAY736

This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum...

Enrolling
Acute-On-Chronic Liver Failure
Other: Standard Medical Treatment
Biological: SMT + PE-A 5%
Locations recently updated

This single and multiple ascending dose (SAD and MAD) study evaluates PHIN-214, being studied to determine the safety, tolerability, and pharmacokine...

Enrolling
Cirrhosis, Liver
Liver Fibrosis
Drug: PHIN-214 Subcutaneous injection

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: Cilofexor (CILO)/Firsocostat (FIR)
Drug: PTM SEMA

The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderat...

Enrolling
Ulcerative Colitis
Drug: Tilpisertib Fosmecarbil
Drug: Placebo

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple asce...

Active, not recruiting
Primary Biliary Cholangitis
Drug: CNP-104
Drug: Placebo

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of the Fixed-Dose Combination (FDC) of Obeticholic Acid (OCA) and Bezafibrate (...

Invitation-only
Primary Biliary Cholangitis
Drug: FDC tablet (OCA 5 mg + BZF 400 mg SR)

Trial sponsors

Gilead Sciences logo
A
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
Enanta Pharmaceuticals logo
Grifols logo
Mirum Pharmaceuticals logo
G
I
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems